Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA September 600x60px
Document › Details

Agilent Technologies Inc.. (9/19/14). "Press Release: Agilent Technologies Calls for Partial Redemption of Outstanding 6.5 Percent Senior Notes Due November 2017". Santa Clara, CA.

Organisation Organisation Keysight Technologies Inc.
Products Product analytical instrument
  Product 2 finance
Person Person Drake, Michele (Agilent 201506 Manager Corporate Media Relations)
     


Agilent Technologies Inc. (NYSE: A) today announced it will redeem $500 million of $600 million outstanding 6.50 percent senior notes due November 2017 on Oct. 20, 2014, the redemption date. This decision is consistent with Agilent's intention to resize its debt portfolio in connection with the expected spinoff of Keysight Technologies.

The redemption price is equal to the sum of the principal amount of the notes outstanding-a make-whole premium that will be calculated three business days prior to the redemption date in accordance with the related indenture-and accrued and unpaid interest on the notes up to but not including the redemption date.

This is not an offer to sell or a solicitation of an offer to buy any securities.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.

In September 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. On Aug. 1, 2014, the company's electronic measurement business began operating as Keysight Technologies, Inc., a wholly owned subsidiary. The separation is expected to be completed in early November 2014.


Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the company's expected redemption of senior notes, debt portfolio and the separation of Agilent and Keysight. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers' businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.

In addition, other risks that Agilent faces include those detailed in Agilent's filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

# # #

Contact:

Michele Drake
+1 408 345 8396
michele_drake@agilent.com

Investor Contact:

Alicia Rodriguez
+1 408 345 8948
alicia_rodriguez@agilent.com

   
Record changed: 2016-03-19

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Agilent (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px